top of page
The Professional Network for Healthcare Experts
Lupin and Sandoz launch Ranluspec ranibizumab biosimilar across Europe following EC approval
Lupin and commercial partner Sandoz have begun launching Ranluspec, a ranibizumab biosimilar, across European markets excluding Germany, expanding commercial competition in treatments for retinal vascular diseases.
nuaxia
56 minutes ago2 min read
FDA approves STADA and Xbrane Lucamzi ranibizumab biosimilar for retinal diseases
The FDA has approved Lucamzi, a ranibizumab biosimilar developed by Xbrane Biopharma and commercialised through STADA, expanding treatment competition in retinal diseases.
nuaxia
Oct 302 min read
bottom of page